Tc-3PRGD SPECT Predicts the Outcome of Endostar and Cisplatin Therapy in Xenograft Animals

• Main Authors: Wei Sun, Guifu He, Mingming Zhang, Yi Zhao, Hongmei Yu, Yi Li, Wei Wu, Tiefeng Ji
• Format: Article
• Language: English
• Published: SAGE Publishing 2019-10-01
• Series: Dose-Response
• Online Access: https://doi.org/10.1177/1559325819882544

Aims: Our study was designed to investigate the usefulness of 99m Tc-3PRGD 2 single-photon emission computed tomography (SPECT) for noninvasively monitoring the response of integrin α v β 3 expression to antiangiogenic treatment with endostar and cisplatin in xenograft animals. Methods: 99m Tc-3PRGD 2 SPECT imaging was performed at days 0, 7, 14, and 21. Tumors were harvested at all imaging time points for Western blotting and histopathological analysis. Result: In 99m Tc-3PRGD 2 SPECT imaging, the radioactivity accumulation of NaCl group rised gradually in the first half and dispersed on day 21 due to the necrosis of the tumor. While the radioactivity accumulation of treated groups gradually decreased throughout the course. The downtrend of tumor to nontumor ratio in endostar-treated group was more remarkable than cisplatin-treated group. The expression of intergrin α v β 3 of treated groups was lower than NaCl group from day 14. The expression of intergrin α v β 3 of endostar-treated group was significantly lower than cisplatin-treated group from baseline onward. Conclusion: It’s demonstrated that the 99m Tc-3PRGD 2 could noninvasively visualize and semiquantify tumor angiogenesis in the xenograft model and monitor the response to the antiangiogenic therapy of endostar and cisplatin effectively. It also can predict the outcome of endostar and cisplatin therapy in xenograft animals.